eHealth shares soar as Q2 revenue tops estimates, guidance raised

eHealth, Inc. (EHTH) shares surged 29% after the company reported second-quarter revenue of $60.8 million, significantly exceeding analyst estimates of $49.94 million, alongside an adjusted EPS beat. The online health insurance marketplace also substantially raised its full-year 2025 revenue guidance to $525-$565 million, and improved its GAAP net income and adjusted EBITDA forecasts. This strong performance and improved outlook were bolstered by positive net adjustment revenue and a 24% reduction in Medicare marketing spend, signaling operational strength despite a year-over-year revenue decline.

Analysis

eHealth, Inc. (EHTH) experienced a significant 29% share price increase following the release of its second-quarter results, which substantially surpassed analyst expectations and were accompanied by a robustly upgraded full-year outlook. The company reported Q2 revenue of $60.8 million, beating the consensus estimate of $49.94 million, although this figure represents an 8% decline year-over-year. The adjusted loss per share of $0.98 was also narrower than the anticipated loss of $1.19. A key factor in the revenue beat was positive net adjustment revenue, which grew to $17.8 million from $11.5 million in the prior year's quarter. More critically for investor sentiment, eHealth raised its full-year 2025 guidance, now projecting revenue between $525 million and $565 million and, most notably, guiding for a GAAP net income of $5 million to $26 million, a significant improvement from its prior forecast which included a potential net loss. This improved profitability is supported by operational efficiencies, including a 24% reduction in variable marketing spend within its Medicare segment and a GAAP net loss that narrowed to $17.4 million from $28 million year-over-year. Management anticipates elevated consumer shopping activity in the upcoming Medicare Annual Enrollment Period, suggesting potential tailwinds.

Key Decisions for Investors

• The substantial upward revision to full-year guidance for revenue, adjusted EBITDA, and particularly GAAP net income signals a potential operational turnaround, which may warrant a re-evaluation of the company's valuation for long-term investors.
• Investors should monitor execution during the upcoming Medicare Annual Enrollment Period to confirm that the company can translate expected market activity into top-line growth, especially given the 8% year-over-year revenue decline in Q2.
• The improved profitability outlook is heavily dependent on continued cost discipline, so tracking operating leverage and marketing spend efficiency will be critical to validating the company's ability to achieve its new earnings targets.